Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Tuberculosis-Pipeline Review, H1 2015

Tuberculosis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Tuberculosis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Tuberculosis-Pipeline Review, H1 2015', provides an overview of the Tuberculosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Tuberculosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Tuberculosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Tuberculosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Tuberculosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 6

Tuberculosis Overview 7

Therapeutics Development 8

Tuberculosis-Therapeutics under Development by Companies 10

Tuberculosis-Therapeutics under Investigation by Universities/Institutes 16

Tuberculosis-Pipeline Products Glance 21

Tuberculosis-Products under Development by Companies 25

Tuberculosis-Products under Investigation by Universities/Institutes 32

Tuberculosis-Companies Involved in Therapeutics Development 37

Tuberculosis-Therapeutics Assessment 94

Drug Profiles 105

Tuberculosis-Recent Pipeline Updates 307

Tuberculosis-Dormant Projects 325

Tuberculosis-Discontinued Products 331

Tuberculosis-Product Development Milestones 332

Appendix 340

List of Tables

Number of Products under Development for Tuberculosis, H1 2015 26

Number of Products under Development for Tuberculosis-Comparative Analysis, H1 2015 27

Number of Products under Development by Companies, H1 2015 29

Number of Products under Development by Companies, H1 2015 (Contd..1) 30

Number of Products under Development by Companies, H1 2015 (Contd..2) 31

Number of Products under Development by Companies, H1 2015 (Contd..3) 32

Number of Products under Development by Companies, H1 2015 (Contd..4) 33

Number of Products under Investigation by Universities/Institutes, H1 2015 35

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 36

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 37

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 38

Comparative Analysis by Late Stage Development, H1 2015 39

Comparative Analysis by Clinical Stage Development, H1 2015 40

Comparative Analysis by Early Stage Development, H1 2015 41

Comparative Analysis by Unknown Stage Development, H1 2015 42

Products under Development by Companies, H1 2015 43

Products under Development by Companies, H1 2015 (Contd..1) 44

Products under Development by Companies, H1 2015 (Contd..2) 45

Products under Development by Companies, H1 2015 (Contd..3) 46

Products under Development by Companies, H1 2015 (Contd..4) 47

Products under Development by Companies, H1 2015 (Contd..5) 48

Products under Development by Companies, H1 2015 (Contd..6) 49

Products under Investigation by Universities/Institutes, H1 2015 50

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 51

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 52

Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 53

Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 54

Tuberculosis-Pipeline by Abera Bioscience AB, H1 2015 55

Tuberculosis-Pipeline by Achillion Pharmaceuticals, Inc., H1 2015 56

Tuberculosis-Pipeline by Akthelia pharmaceuticals ehf, H1 2015 57

Tuberculosis-Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 58

Tuberculosis-Pipeline by Archivel Farma S.L., H1 2015 59

Tuberculosis-Pipeline by AstraZeneca Plc, H1 2015 60

Tuberculosis-Pipeline by BioDiem Ltd, H1 2015 61

Tuberculosis-Pipeline by Biomar Microbial Technologies, H1 2015 62

Tuberculosis-Pipeline by Bioversys AG, H1 2015 63

Tuberculosis-Pipeline by Cellceutix Corporation, H1 2015 64

Tuberculosis-Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2015 65

Tuberculosis-Pipeline by CureVac GmbH, H1 2015 66

Tuberculosis-Pipeline by Dafra Pharma International Ltd., H1 2015 67

Tuberculosis-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 68

Tuberculosis-Pipeline by Eisai Co., Ltd., H1 2015 69

Tuberculosis-Pipeline by Eli Lilly and Company, H1 2015 70

Tuberculosis-Pipeline by Ensoltek Co., Ltd., H1 2015 71

Tuberculosis-Pipeline by EpiVax, Inc., H1 2015 72

Tuberculosis-Pipeline by FIT Biotech Oy, H1 2015 73

Tuberculosis-Pipeline by GangaGen Inc., H1 2015 74

Tuberculosis-Pipeline by GlaxoSmithKline Plc, H1 2015 75

Tuberculosis-Pipeline by Globeimmune, Inc., H1 2015 76

Tuberculosis-Pipeline by Imaxio SA, H1 2015 77

Tuberculosis-Pipeline by Immunitor, Inc., H1 2015 78

Tuberculosis-Pipeline by ImmunoBiology Limited, H1 2015 79

Tuberculosis-Pipeline by Immunovaccine, Inc., H1 2015 80

Tuberculosis-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 81

Tuberculosis-Pipeline by iThemba Pharmaceuticals (Pty) Ltd., H1 2015 82

Tuberculosis-Pipeline by Johnson & Johnson, H1 2015 83

Tuberculosis-Pipeline by Lipotek Pty Ltd., H1 2015 84

Tuberculosis-Pipeline by Microbion Corporation, H1 2015 85

Tuberculosis-Pipeline by Microbiotix, Inc., H1 2015 86

Tuberculosis-Pipeline by NEARMEDIC PLUS, Ltd, H1 2015 87

Tuberculosis-Pipeline by Novartis AG, H1 2015 88

Tuberculosis-Pipeline by Okklo Life Sciences BV, H1 2015 89

Tuberculosis-Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H1 2015 90

Tuberculosis-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 91

Tuberculosis-Pipeline by Polymun Scientific Immunbiologische Forschung GmbH, H1 2015 92

Tuberculosis-Pipeline by Prokarium Limited, H1 2015 93

Tuberculosis-Pipeline by Sanofi, H1 2015 94

Tuberculosis-Pipeline by Sanofi Pasteur SA, H1 2015 95

Tuberculosis-Pipeline by Sarepta Therapeutics, Inc., H1 2015 96

Tuberculosis-Pipeline by SEEK Group, H1 2015 97

Tuberculosis-Pipeline by Sequella, Inc., H1 2015 98

Tuberculosis-Pipeline by Snowdon Inc., H1 2015 99

Tuberculosis-Pipeline by Sphaera Pharma Pvt. Ltd., H1 2015 100

Tuberculosis-Pipeline by Syntrix Biosystems, Inc., H1 2015 101

Tuberculosis-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 102

Tuberculosis-Pipeline by TetraLogic Pharmaceuticals, H1 2015 103

Tuberculosis-Pipeline by Theravectys S.A., H1 2015 104

Tuberculosis-Pipeline by Transgene SA, H1 2015 105

Tuberculosis-Pipeline by TVAX Biomedical, Inc., H1 2015 106

Tuberculosis-Pipeline by Vaccibody AS, H1 2015 107

Tuberculosis-Pipeline by Vakzine Projekt Management GmbH, H1 2015 108

Tuberculosis-Pipeline by Vaxil Bio Therapeutics Ltd., H1 2015 109

Tuberculosis-Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 110

Tuberculosis-Pipeline by Vichem Chemie Research Ltd., H1 2015 111

Assessment by Monotherapy Products, H1 2015 112

Assessment by Combination Products, H1 2015 113

Number of Products by Stage and Target, H1 2015 115

Number of Products by Stage and Mechanism of Action, H1 2015 118

Number of Products by Stage and Route of Administration, H1 2015 120

Number of Products by Stage and Molecule Type, H1 2015 122

Tuberculosis Therapeutics-Recent Pipeline Updates, H1 2015 325

Tuberculosis-Dormant Projects, H1 2015 343

Tuberculosis-Dormant Projects (Contd..1), H1 2015 344

Tuberculosis-Dormant Projects (Contd..2), H1 2015 345

Tuberculosis-Dormant Projects (Contd..3), H1 2015 346

Tuberculosis-Dormant Projects (Contd..4), H1 2015 347

Tuberculosis-Dormant Projects (Contd..5), H1 2015 348

Tuberculosis-Discontinued Products, H1 2015 349

List of Figures

Number of Products under Development for Tuberculosis, H1 2015 26

Number of Products under Development for Tuberculosis-Comparative Analysis, H1 2015 27

Number of Products under Development by Companies, H1 2015 28

Number of Products under Investigation by Universities/Institutes, H1 2015 34

Comparative Analysis by Late Stage Development, H1 2015 39

Comparative Analysis by Clinical Stage Development, H1 2015 40

Comparative Analysis by Early Stage Products, H1 2015 41

Assessment by Monotherapy Products, H1 2015 112

Number of Products by Top 10 Targets, H1 2015 114

Number of Products by Stage and Top 10 Targets, H1 2015 114

Number of Products by Top 10 Mechanism of Actions, H1 2015 117

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 117

Number of Products by Top 10 Routes of Administration, H1 2015 119

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 119

Number of Products by Top 10 Molecule Types, H1 2015 121

Number of Products by Stage and Top 10 Molecule Types, H1 2015 121

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abera Bioscience AB

Achillion Pharmaceuticals, Inc.

Akthelia pharmaceuticals ehf

Anacor Pharmaceuticals, Inc.

Archivel Farma S.L.

AstraZeneca Plc

BioDiem Ltd

Biomar Microbial Technologies

Bioversys AG

Cellceutix Corporation

Chongqing Zhifei Biological Products Co., Ltd.

CureVac GmbH

Dafra Pharma International Ltd.

Daiichi Sankyo Company, Limited

Eisai Co., Ltd.

Eli Lilly and Company

Ensoltek Co., Ltd.

EpiVax, Inc.

FIT Biotech Oy

GangaGen Inc.

GlaxoSmithKline Plc

Globeimmune, Inc.

Imaxio SA

Immunitor, Inc.

ImmunoBiology Limited

Immunovaccine, Inc.

Inovio Pharmaceuticals, Inc.

iThemba Pharmaceuticals (Pty) Ltd.

Johnson & Johnson

Lipotek Pty Ltd.

Microbion Corporation

Microbiotix, Inc.

NEARMEDIC PLUS, Ltd

Novartis AG

Okklo Life Sciences BV

Orchid Chemicals & Pharmaceuticals Ltd

Otsuka Holdings Co., Ltd.

Polymun Scientific Immunbiologische Forschung GmbH

Prokarium Limited

Sanofi

Sanofi Pasteur SA

Sarepta Therapeutics, Inc.

SEEK Group

Sequella, Inc.

Snowdon Inc.

Sphaera Pharma Pvt. Ltd.

Syntrix Biosystems, Inc.

Takeda Pharmaceutical Company Limited

TetraLogic Pharmaceuticals

Theravectys S.A.

Transgene SA

TVAX Biomedical, Inc.

Vaccibody AS

Vakzine Projekt Management GmbH

Vaxil Bio Therapeutics Ltd.

Vertex Pharmaceuticals Incorporated

Vichem Chemie Research Ltd.

Tuberculosis Therapeutic Products under Development, Key Players in Tuberculosis Therapeutics, Tuberculosis Pipeline Overview, Tuberculosis Pipeline, Tuberculosis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com